

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): May 8, 2014**

**MEDNAX, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Florida**

(State or Other Jurisdiction of  
Incorporation)

**001-12111**

(Commission File  
Number)

**26-3667538**

(IRS Employer Identification No.)

**1301 Concord Terrace  
Sunrise, Florida 33323**

(Address of principal executive office) (zip code)

**Registrant's telephone number, including area code (954) 384-0175**

---

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 8, 2014, MEDNAX, Inc., a Florida corporation (the “Company”), held its 2014 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 100,199,859 shares of common stock outstanding and entitled to vote, 90,522,627 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

*Proposal 1:* All of the Board’s nominees for Director were elected to serve until the Company’s 2015 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

<u>Name</u>	<u>For</u>	<u>Withheld</u>	<u>Broker Non-Vote</u>
Cesar L. Alvarez	70,395,459	16,370,025	3,757,143
Waldemar A. Carlo, M.D.	75,661,374	11,104,110	3,757,143
Michael B. Fernandez	73,507,684	13,257,800	3,757,143
Roger K. Freeman, M.D.	84,024,403	2,741,081	3,757,143
Paul G. Gabos	84,581,113	2,184,371	3,757,143
Pascal J. Goldschmidt, M.D.	86,310,123	455,361	3,757,143
Manuel Kadre	78,063,220	8,702,264	3,757,143
Roger J. Medel, M.D.	84,876,149	1,889,335	3,757,143
Donna E. Shalala, Ph.D.	86,730,686	34,798	3,757,143
Enrique J. Sosa, Ph.D.	86,471,707	293,777	3,757,143

*Proposal 2:* The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered certified public accounting firm for the 2014 fiscal year was ratified by the shareholders, by the votes set forth in the table below:

<u>For</u>	<u>Against</u>	<u>Abstained</u>	<u>Broker Non-Vote</u>
88,085,579	2,404,594	32,454	0

*Proposal 3:* The shareholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, by the votes set forth in the table below:

<b>For</b>	<b>Against</b>	<b>Abstained</b>	<b>Broker Non-Vote</b>
70,256,610	15,405,947	1,102,927	3,757,143

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDNAX, INC.**

Date: May 8, 2014

By: /s/ Vivian Lopez-Blanco  
Vivian Lopez-Blanco  
Chief Financial Officer